JAMA DermClinical trial
Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
Two Phase 3 UP-AA Randomized Clinical Trials.
ConclusionIn these 2 parallel phase 3 replicate randomized clinical trials, upadacitinib demonstrated a positive benefit-risk profile in adults and adolescents with severe AA. Upadacitinib may be a potentially effective treatment option for this patient population.
Mostaghimi A, Gooderham MJ, … senior author Passeron TJAMA Dermatology